	US 12,290,554 B2
	Compositions for optimized BCR-ABL peptide vaccines
David Kenneth Gifford, Newton, MA (US); and Brandon Carter, Cambridge, MA (US)
Assigned to Think Therapeutics, Inc., Newton, MA (US)
Filed by Think Therapeutics, Inc., Newton, MA (US)
Filed on Sep. 21, 2022, as Appl. No. 17/934,067.
Claims priority of provisional application 63/249,235, filed on Sep. 28, 2021.
Prior Publication US 2023/0099121 A1, Mar. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); A61K 39/00 (2006.01); C12N 15/85 (2006.01)

CPC A61K 39/001197 (2018.08) [A61K 39/00 (2013.01); C12N 15/85 (2013.01); C12N 2510/00 (2013.01)]

16 Claims

1. A composition comprising one or more polynucleotides encoding at least two amino acid sequences, wherein the at least two amino acid sequences are selected from the group consisting of SEQ ID NOs: 1 to 8, SEQ ID NOs: 10 to 17, and SEQ ID NOs: 19 to 44.